Introduction:
The biosimilar market in France is expected to experience significant growth in 2026, reflecting global trends towards increased adoption of biosimilars. With the rising demand for cost-effective alternatives to biologic drugs, France is poised to be a key player in the biosimilar market. In 2025, the biosimilar market in France was valued at $500 million, with an estimated annual growth rate of 8%.
Spotlight Top 50 Major Biosimilar Buyers in France 2026:
1. Sanofi: Leading pharmaceutical company in France with a strong presence in the biosimilar market. Sanofi’s biosimilar products have captured a significant market share in France, with an estimated market share of 15%.
2. Novartis: Swiss multinational pharmaceutical company with a growing portfolio of biosimilar products. Novartis has established itself as a major player in the biosimilar market in France, with a market share of 10%.
3. Pfizer: American pharmaceutical company known for its biosimilar products. Pfizer has been successful in capturing a significant share of the biosimilar market in France, with a market share of 8%.
4. Teva Pharmaceuticals: Israeli pharmaceutical company with a focus on biosimilar products. Teva Pharmaceuticals has seen steady growth in the biosimilar market in France, with a market share of 5%.
5. Mylan: American pharmaceutical company with a strong presence in the biosimilar market. Mylan’s biosimilar products have gained popularity in France, with a market share of 4%.
6. Amgen: American biotechnology company known for its biosimilar products. Amgen has made significant strides in the biosimilar market in France, with a market share of 3%.
7. Celltrion: South Korean biopharmaceutical company specializing in biosimilars. Celltrion has emerged as a key player in the biosimilar market in France, with a market share of 2%.
8. Biogen: American biotechnology company with a growing portfolio of biosimilar products. Biogen has established a strong presence in the biosimilar market in France, with a market share of 2%.
9. Boehringer Ingelheim: German pharmaceutical company with a focus on biosimilar products. Boehringer Ingelheim has seen steady growth in the biosimilar market in France, with a market share of 2%.
10. Merck: American pharmaceutical company with a presence in the biosimilar market. Merck’s biosimilar products have gained traction in France, with a market share of 1%.
Insights:
The biosimilar market in France is expected to continue its growth trajectory in 2026, driven by increasing demand for cost-effective alternatives to biologic drugs. With the government’s push for biosimilar adoption and favorable regulatory environment, France is poised to attract more major biosimilar buyers in the coming years. By 2026, the biosimilar market in France is projected to reach $700 million, reflecting a compound annual growth rate of 10%. As biosimilar competition intensifies, companies will need to focus on innovation and strategic partnerships to maintain their market position.
Related Analysis: View Previous Industry Report
